BE563436A - - Google Patents
Info
- Publication number
- BE563436A BE563436A BE563436DA BE563436A BE 563436 A BE563436 A BE 563436A BE 563436D A BE563436D A BE 563436DA BE 563436 A BE563436 A BE 563436A
- Authority
- BE
- Belgium
- Prior art keywords
- product
- dicyclopropyl
- ketoxime
- pharmaceutical carrier
- per
- Prior art date
Links
- YNMFDPCLPIMRFD-UHFFFAOYSA-N Quercetin-3-o-vicianoside Chemical compound OC1C(O)C(O)COC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 YNMFDPCLPIMRFD-UHFFFAOYSA-N 0.000 claims description 18
- 239000000725 suspension Substances 0.000 claims description 7
- 239000007788 liquid Substances 0.000 claims description 6
- 210000003205 muscle Anatomy 0.000 claims description 5
- 239000007787 solid Substances 0.000 claims description 5
- 206010049816 Muscle tightness Diseases 0.000 claims description 2
- 230000000694 effects Effects 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims 5
- 231100000252 nontoxic Toxicity 0.000 claims 3
- 230000003000 nontoxic effect Effects 0.000 claims 3
- 239000007900 aqueous suspension Substances 0.000 claims 1
- 229940102223 injectable solution Drugs 0.000 claims 1
- 239000003158 myorelaxant agent Substances 0.000 claims 1
- 239000008014 pharmaceutical binder Substances 0.000 claims 1
- 239000000375 suspending agent Substances 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 description 8
- 239000003826 tablet Substances 0.000 description 8
- 239000000203 mixture Substances 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 229920002261 Corn starch Polymers 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- 230000001914 calming effect Effects 0.000 description 4
- 239000008120 corn starch Substances 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 230000002040 relaxant effect Effects 0.000 description 3
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 235000010489 acacia gum Nutrition 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- -1 dicyclopropyl-ketoxime compound Chemical class 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 239000002304 perfume Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 210000002027 skeletal muscle Anatomy 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- GXFZCDMWGMFGFL-KKXMJGKMSA-N (+)-Tubocurarine chloride hydrochloride Chemical compound [Cl-].[Cl-].C([C@H]1[N+](C)(C)CCC=2C=C(C(=C(OC3=CC=C(C=C3)C[C@H]3C=4C=C(C(=CC=4CC[NH+]3C)OC)O3)C=21)O)OC)C1=CC=C(O)C3=C1 GXFZCDMWGMFGFL-KKXMJGKMSA-N 0.000 description 1
- 229940090248 4-hydroxybenzoic acid Drugs 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 241001111317 Chondrodendron tomentosum Species 0.000 description 1
- 206010010305 Confusional state Diseases 0.000 description 1
- 239000008709 Curare Substances 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 239000001785 acacia senegal l. willd gum Substances 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 230000036524 ataraxia Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 210000000715 neuromuscular junction Anatomy 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 239000007968 orange flavor Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 210000000578 peripheral nerve Anatomy 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000003186 pharmaceutical solution Substances 0.000 description 1
- 239000007971 pharmaceutical suspension Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 230000005062 synaptic transmission Effects 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Preparation (AREA)
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BE563436A true BE563436A (enrdf_load_stackoverflow) |
Family
ID=184673
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BE563436D BE563436A (enrdf_load_stackoverflow) |
Country Status (1)
| Country | Link |
|---|---|
| BE (1) | BE563436A (enrdf_load_stackoverflow) |
-
0
- BE BE563436D patent/BE563436A/fr unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE19543271B4 (de) | Orales pharmazeutisches Präparat | |
| EP0287488B1 (fr) | Médicament, produit diététique et produit d'hygiène sous la forme d'une composition pulvérulente obtenue par adsorption de principes actifs sur un sucre à dissolution rapide et procédé d'obtention de ladite composition | |
| CA2680433C (fr) | Nouvelle composition a base d'oxime de cholest-4-en-3-one | |
| BE1015217A5 (enrdf_load_stackoverflow) | ||
| CH648484A5 (de) | Pharmazeutische zubereitung eines festen medikamentmaterials. | |
| WO1994013287A1 (de) | Verwendung von 2-amino-6-a-propyl-amino-4,5,6,7-tetrahydrobenzothiazol (pramipexol) als arzneimittel mit antidepressiver wirkung | |
| EP0077723A1 (fr) | Composition pharmaceutique à action antagoniste périphérique des narcotiques | |
| EP0277352B1 (de) | Synergistische Kombination von Azelastin und Theophyllin oder Azelastin und Beta-Mimetika | |
| WO1998011881A1 (fr) | Compositions pharmaceutiques comprenant de l'amisulpride et leurs applications therapeutiques | |
| LU86901A1 (fr) | Compositions pharmaceutiques de polypeptides adaptees a la resorption gastro-intestinale | |
| BE1010972A6 (fr) | Composition pharmaceutique antituberculeuse et procede destine a produire ladite composition. | |
| CH684629A5 (fr) | Formulations pour voie orale d'ubidécarénone sous la forme de solutions aqueuses. | |
| BE563436A (enrdf_load_stackoverflow) | ||
| FR2664814A1 (fr) | Compositions pharmaceutiques solides et leur procede de preparation. | |
| FR2467596A1 (fr) | Compositions pharmaceutiques de tiaramide ou de son sel et d'un agent reglant la dissolution, a longue duree d'action | |
| US2916417A (en) | Article of manufacture | |
| BE1004243A3 (fr) | Compositions pharmaceutiques du type a liberation prolongee destinees a l'administration par voie orale et leur procede de preparation. | |
| LU85791A1 (fr) | Compositions de bromocriptine | |
| JPH06506706A (ja) | ベンゾフルメトールを含有する抗マラリア性の相乗作用組成物 | |
| BE563376A (enrdf_load_stackoverflow) | ||
| EP0315197A1 (de) | Oral anzuwendende Arzneiform zur einmal täglichen Behandlung der Hypertonie mit Diltiazemhydrochlorid | |
| FR2650502A1 (fr) | Nouvelle forme galenique orale ameliorant la biodisponibilite | |
| US3495005A (en) | Compositions and methods for suppressing appetite with combinations of amphetamine and thioridazine | |
| FR2558728A1 (fr) | Composition pharmaceutique antipaludeenne a base de quinine, quinidine et cinchonine | |
| CH640137A5 (fr) | Composition pharmaceutique contenant de la s-adenosyl-l-homocysteine. |